EC
OBIO icon

Elequin Capital’s Orchestra BioMed OBIO Stock Holding History

Elequin Capital’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,542
Closed -$15.4K – 471
2022
Q4 		$15.4K Hold
1,542
– – ﹤0.01% 431
2022
Q3 		$15K Sell
1,542
-48,458
-97% -$480K 0.01% 187
2022
Q2 		$498K Buy
+50,000
New +$497K 0.11% 47

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SFG
SVB Financial Group Dallas, Texas $434K AUM 277.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Elequin Capital's OBIO Position: Q1 2023 in Review

Elequin Capital sold out of Orchestra BioMed (OBIO) in Q1 2023, closing a stake of 1,542 shares — an estimated $15.4K sold.

Elequin Capital first reported a position in OBIO in Q2 2022 and held it in 3 quarters. The position peaked at $498K in Q2 2022. 22 funds tracked by Wall St. Rank hold OBIO as of Q1 2023.

  • Elequin Capital reported no remaining Orchestra BioMed position as of Q1 2023 after selling out during the quarter.
  • Elequin Capital sold 1,542 Orchestra BioMed shares in Q1 2023, an estimated $15.4K.
  • Elequin Capital first reported a position in Orchestra BioMed in Q2 2022 and held it in 3 quarters.
  • Elequin Capital's Orchestra BioMed position peaked at $498K in Q2 2022.
  • 22 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2023.

Based on Elequin Capital's 13F filing for Q1 2023, filed 11 May 2023.